ISRCTN11081180已完成未知
Does allopurinol reduce right ventricular mass in lung disease associated pulmonary hypertension?
HS Tayside - University of Dundee0 个研究点目标入组 71 人开始时间: 2015年2月17日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 71
研究概览
简要总结
2020 results in https://pubmed.ncbi.nlm.nih.gov/32904701/ (added 29/12/2020)
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Aged 18 years or over
- •2. Previously diagnosed with COPD or ILD
- •3. Screening echocardiography based diagnosis of PH as indicated by RVSP >25 mmHg, and/or PAT <110 m/s2 and/or RVM >5.5 mm
- •4. Stable lung disease medication for at least 2 weeks prior to consent
- •5. Women of child bearing potential must agree to scheduled pregnancy testing prior to and during study treatment period and to use an appropriate method of contraception if sexually active
排除标准
- •1. Documented allergy or intolerance to allopurinol
- •2. Objection to taking capsules made from animal-sourced gelatine
- •3. Left Ventricular Ejection Fraction <45% on echocardiography screening
- •4. Severe aortic stenosis on echocardiography (screening)
- •5. Already had gout or currently taking allopurinol
- •6. Severe hepatic disease
- •7. Renal disease; CKD class 3B or greater
- •8. Taking prohibited medication; azathioprine, 6 mercaptopurine, or theophylline
- •9. Malignancy (receiving active treatment) or other life threatening diseases
- •10. Pregnant or lactating
- •11. Women unwilling to agree to use an appropriate method of contraception during the
- •study treatment period if sexually active
- •12. Any contraindication to MRI (claustrophobia, metal implants)
- •13. Patients who have participated in any other clinical trial of an investigational medicinal product within the previous 30 days will be excluded
- •14. Any other considered by a study physician to be inappropriate for inclusion
研究者
相似试验
进行中（未招募）
1 期
The ALPHA Trialright ventricular hypertrophy associated with COPD or Interstitial Lung Disease and pulmonary hypertensionMedDRA version: 17.1 Level: LLT Classification code 10010952 Term: COPD System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersMedDRA version: 17.1 Level: PT Classification code 10022611 Term: Interstitial lung disease System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersMedDRA version: 17.1 Level: PT Classification code 10037400 Term: Pulmonary hypertension System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersMedDRA version: 17.1 Level: PT Classification code 10050326 Term: Right ventricular hypertrophy System Organ Class: 10007541 - Cardiac disordersEUCTR2014-002305-38-GBniversity of Dundee/ NHS Tayside72
已完成
不适用
Does allopurinol reduce thickening of the left ventricle of the heart in patients with treated hypertension?Essential hypertensives with left ventricular hypertrophyCirculatory SystemISRCTN40476871The University of Dundee and NHS Tayside (UK)72
进行中（未招募）
1 期
The Altered study: Does Allopurinol regress left ventricular hypertrophy in End stage Renal DiseaseRenal failure and left ventricular hypertrophyEUCTR2013-001436-22-GBniversity of Dundee/NHS Tayside86
进行中（未招募）
1 期
The ALLAY trialeft ventricular hypertrophy in hypertensionMedDRA version: 17.0 Level: PT Classification code 10049773 Term: Left ventricular hypertrophy System Organ Class: 10007541 - Cardiac disordersMedDRA version: 17.0 Level: PT Classification code 10015488 Term: Essential hypertension System Organ Class: 10047065 - Vascular disordersEUCTR2014-002083-33-GBniversity of Dundee/NHS Tayside66
已完成
不适用
Does allopurinol prevent adverse left ventricular remodelling post-myocardial infarction?Myocardial infarctionCirculatory SystemISRCTN57354520niversity of Dundee (UK)36